Apr. 2 at 12:37 PM
PRISM MedTech Index Addition:
$BIAF
We’re adding bioAffinity Technologies to the PRISM MedTech Index.
The company is gaining traction with its noninvasive lung cancer diagnostic, CyPath® Lung, which uses flow cytometry and AI to support early detection and risk assessment. Preliminary Q1 2026 results showed 146% year-over-year unit growth, reflecting increasing physician adoption and expanding clinical use.
CyPath® Lung is positioned within a large and growing market, with pulmonary nodule detection and lung cancer surveillance expected to expand meaningfully over the next several years. As screening increases, the need for accurate, noninvasive diagnostic tools continues to rise.
With strong growth, real-world clinical traction, and exposure to early cancer detection, bioAffinity adds a differentiated diagnostics layer to the PRISM MedTech Index.
https://prismmarketview.com/companies/bioaffinity-technologies-inc/
